FR10C0041I2 - - Google Patents
Info
- Publication number
- FR10C0041I2 FR10C0041I2 FR10C0041C FR10C0041C FR10C0041I2 FR 10C0041 I2 FR10C0041 I2 FR 10C0041I2 FR 10C0041 C FR10C0041 C FR 10C0041C FR 10C0041 C FR10C0041 C FR 10C0041C FR 10C0041 I2 FR10C0041 I2 FR 10C0041I2
- Authority
- FR
- France
- Prior art keywords
- tomoxetine
- deficit
- hyperactivity disorder
- uptake inhibitor
- norepinephrine uptake
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/371,341 US5658590A (en) | 1995-01-11 | 1995-01-11 | Treatment of attention-deficit/hyperactivity disorder |
Publications (2)
Publication Number | Publication Date |
---|---|
FR10C0041I1 FR10C0041I1 (fr) | 2010-10-15 |
FR10C0041I2 true FR10C0041I2 (fr) | 2011-04-29 |
Family
ID=23463572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR10C0041C Active FR10C0041I2 (fr) | 1995-01-11 | 2010-08-20 |
Country Status (28)
Country | Link |
---|---|
US (1) | US5658590A (fr) |
EP (1) | EP0721777B1 (fr) |
JP (2) | JPH10512262A (fr) |
KR (1) | KR19980701276A (fr) |
CN (2) | CN1168095A (fr) |
AT (1) | ATE222757T1 (fr) |
AU (1) | AU688665B2 (fr) |
BR (1) | BR9606903A (fr) |
CA (1) | CA2209735C (fr) |
CZ (1) | CZ292226B6 (fr) |
DE (2) | DE122005000011I2 (fr) |
DK (1) | DK0721777T3 (fr) |
ES (1) | ES2181845T3 (fr) |
FI (1) | FI119354B (fr) |
FR (1) | FR10C0041I2 (fr) |
HU (1) | HU227306B1 (fr) |
LU (1) | LU91238I2 (fr) |
NL (1) | NL300180I2 (fr) |
NO (1) | NO317027B1 (fr) |
NZ (1) | NZ301500A (fr) |
PL (1) | PL187573B1 (fr) |
PT (1) | PT721777E (fr) |
RO (1) | RO118374B1 (fr) |
RU (1) | RU2163802C2 (fr) |
SI (1) | SI0721777T1 (fr) |
TR (1) | TR199700627T1 (fr) |
UA (1) | UA43385C2 (fr) |
WO (1) | WO1996021430A1 (fr) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
GB9613243D0 (en) * | 1996-06-25 | 1996-08-28 | Britannia Pharmaceuticals Ltd | Attention deficit hyperactive disorder |
AU9214498A (en) * | 1997-09-23 | 1999-04-12 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
UA57107C2 (uk) * | 1997-09-23 | 2003-06-16 | Елі Ліллі Енд Компані | Спосіб лікування розладу поведінки |
UA56257C2 (uk) * | 1997-09-23 | 2003-05-15 | Елі Ліллі Енд Компані | Спосіб лікування неадекватної визивної поведінки |
US5902797A (en) * | 1997-11-10 | 1999-05-11 | Beth Israel Deaconess Medical Center | Nutritional supplement for use in the treatment of attention deficit |
CN1301164A (zh) * | 1998-04-09 | 2001-06-27 | 法玛西雅厄普约翰美国公司 | 神经病症的新疗法 |
US6586427B2 (en) | 1998-04-09 | 2003-07-01 | Pharmacia & Upjohn Company | Treatments for nervous disorders |
ES2351149T3 (es) * | 1998-11-09 | 2011-02-01 | Biogen Idec Inc. | Anticuerpo quimérico dirigido contra cd20, el rituxan, para uso en el tratamiento de la leucemia linfocítica crónica. |
US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
US6898455B2 (en) * | 1999-10-29 | 2005-05-24 | The Mclean Hospital Corporation | Method for providing optimal drug dosage |
US6400978B1 (en) | 1999-10-29 | 2002-06-04 | The Mclean Hospital Corporation | Method and apparatus for detecting mental disorders |
BR0108980A (pt) * | 2000-03-07 | 2003-06-03 | Lilly Co Eli | Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina |
US20020016334A1 (en) * | 2000-07-31 | 2002-02-07 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) |
US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
US20040034106A1 (en) * | 2001-11-06 | 2004-02-19 | Read Holly Ann | Treatment of anxiety disorders |
WO2003049724A1 (fr) * | 2001-12-11 | 2003-06-19 | Eli Lilly And Company | Utilisation d'inhibiteurs de recaptage de la noradrenaline dans le traitement de la defaillance cognitive |
WO2004017977A2 (fr) | 2002-08-23 | 2004-03-04 | Eli Lilly And Company | Derives de morpholine |
GB0219687D0 (en) | 2002-08-23 | 2002-10-02 | Lilly Co Eli | Benzyl morpholine derivatives |
US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
WO2004103356A2 (fr) * | 2003-05-15 | 2004-12-02 | Eli Lilly And Company | Traitement du dysfonctionnement emotionnel |
WO2005011583A2 (fr) * | 2003-07-28 | 2005-02-10 | Leslie Joe Dunaway | Traitement de la rhinite allergique et de l'asthme |
CA2536161A1 (fr) * | 2003-08-27 | 2005-03-10 | Eli Lilly And Company | Traitement des troubles profonds du developpement au moyen d'inhibiteurs de la recapture de la norepinephrine |
EP1660064A2 (fr) * | 2003-08-27 | 2006-05-31 | Eli Lilly And Company | Traitement de difficultes d'apprentissage et de troubles de la motricite faisant appel a des inhibiteurs de la recapture de la noradrenaline |
WO2005065673A1 (fr) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Preparations d'atomoxetine |
US8545881B2 (en) | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
WO2005115396A2 (fr) * | 2004-05-27 | 2005-12-08 | Warner-Lambert Company Llc | Combinaison therapeutique pour troubles d'hyperactivite avec deficit de l'attention |
US7439399B2 (en) * | 2004-06-28 | 2008-10-21 | Teva Pharmaceutical Fine Chemicals | Processes for the preparation of atomoxetine hydrochloride |
CA2561387A1 (fr) * | 2004-06-28 | 2006-01-12 | Teva Pharmaceutical Fine Chemicals S.R.L. | Impurete d'atomoxetine isolee, procedes d'obtention d'impuretes d'atomoxetine et leurs utilisations comme normes de reference |
EP1768949A2 (fr) * | 2004-07-22 | 2007-04-04 | Teva Pharmaceutical Fine Chemicals S.R.L. | Polymorphes du chlorhydrate d'atomoxetine |
US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
EP2417969A1 (fr) | 2004-10-21 | 2012-02-15 | Aptalis Pharmatech, Inc. | Compositions pharmaceutiques à saveur masquée avec substances porogènes gastrosolubles |
US7569729B2 (en) * | 2005-04-05 | 2009-08-04 | Teva Pharmaceutical Fine Chemicals S.R.L. | Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
AU2006318476A1 (en) * | 2005-11-23 | 2007-05-31 | Auspex Pharmaceuticals, Inc. | Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity |
JP2009518337A (ja) | 2005-12-07 | 2009-05-07 | エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ | 皮質カテコールアミン作動性神経伝達のモジュレーターとしての二置換フェニルピペリジン |
US20080020387A1 (en) * | 2006-03-31 | 2008-01-24 | Lawrence Donald G | Biomarker-optimized adhd treatment |
US20080146675A1 (en) * | 2006-04-05 | 2008-06-19 | Eugenio Castelli | Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability |
US20080031932A1 (en) * | 2006-08-04 | 2008-02-07 | Watson Laboratories, Inc. | Transdermal atomoxetine formulations and associated methods |
US20080145318A1 (en) * | 2006-12-13 | 2008-06-19 | Midha Kamal K | Atomoxetine formulations and associated methods |
WO2008122019A1 (fr) * | 2007-04-02 | 2008-10-09 | Cypress Biosciences, Inc. | Amélioration de la tolérabilité de la mirtazapine et de la réboxétine par leur utilisation en combinaison |
US20100069390A1 (en) * | 2008-09-05 | 2010-03-18 | Supernus Pharmaceuticals, Inc. | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
RU2395313C2 (ru) * | 2008-10-15 | 2010-07-27 | Татьяна Прохоровна Тетерина | Способ коррекции синдрома дефицита внимания и гиперактивности |
CA2782285A1 (fr) | 2009-12-02 | 2011-06-09 | Luigi Mapelli | Microcapsules de fexofenadine et compositions les contenant |
US8916588B2 (en) | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
SG193587A1 (en) | 2011-03-23 | 2013-10-30 | Ironshore Pharmaceuticals & Dev Inc | Methods and compositions for treatment of attention deficit disorder |
US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US8927010B2 (en) | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
AU2013217013B2 (en) | 2012-02-08 | 2017-04-20 | Supernus Pharmaceuticals, Inc. | Modified release formulations of viloxazine |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
PT2838510T (pt) | 2013-11-08 | 2016-11-23 | Lilly Co Eli | Solução de atomoxetina |
CA2936741C (fr) | 2014-10-31 | 2018-11-06 | Purdue Pharma | Methodes et compositions destinees au traitement du trouble de deficit d'attention |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5457121A (en) * | 1994-09-02 | 1995-10-10 | Eli Lilly And Company | Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake |
ZA958725B (en) * | 1994-10-20 | 1997-04-16 | Lilly Co Eli | Treatment of disorders with duloxetine |
-
1995
- 1995-01-11 US US08/371,341 patent/US5658590A/en not_active Expired - Lifetime
-
1996
- 1996-01-04 CN CN96191412A patent/CN1168095A/zh active Pending
- 1996-01-04 RO RO97-01260A patent/RO118374B1/ro unknown
- 1996-01-04 NZ NZ301500A patent/NZ301500A/en not_active IP Right Cessation
- 1996-01-04 CN CNA2005100832846A patent/CN1781480A/zh active Pending
- 1996-01-04 JP JP8521732A patent/JPH10512262A/ja not_active Withdrawn
- 1996-01-04 PL PL96321273A patent/PL187573B1/pl unknown
- 1996-01-04 WO PCT/US1996/000091 patent/WO1996021430A1/fr not_active Application Discontinuation
- 1996-01-04 KR KR1019970704665A patent/KR19980701276A/ko not_active Application Discontinuation
- 1996-01-04 AU AU46938/96A patent/AU688665B2/en not_active Expired
- 1996-01-04 TR TR97/00627T patent/TR199700627T1/xx unknown
- 1996-01-04 BR BR9606903A patent/BR9606903A/pt unknown
- 1996-01-04 RU RU97113060/14A patent/RU2163802C2/ru active
- 1996-01-04 CA CA002209735A patent/CA2209735C/fr not_active Expired - Lifetime
- 1996-01-04 HU HU9801283A patent/HU227306B1/hu active Protection Beyond IP Right Term
- 1996-01-04 CZ CZ19972145A patent/CZ292226B6/cs not_active IP Right Cessation
- 1996-01-09 ES ES96300157T patent/ES2181845T3/es not_active Expired - Lifetime
- 1996-01-09 SI SI9630534T patent/SI0721777T1/xx unknown
- 1996-01-09 DE DE200512000011 patent/DE122005000011I2/de active Active
- 1996-01-09 DK DK96300157T patent/DK0721777T3/da active
- 1996-01-09 DE DE69623141T patent/DE69623141T2/de not_active Expired - Lifetime
- 1996-01-09 AT AT96300157T patent/ATE222757T1/de active
- 1996-01-09 EP EP96300157A patent/EP0721777B1/fr not_active Expired - Lifetime
- 1996-01-09 PT PT96300157T patent/PT721777E/pt unknown
- 1996-04-01 UA UA97073620A patent/UA43385C2/uk unknown
-
1997
- 1997-07-08 NO NO19973170A patent/NO317027B1/no not_active IP Right Cessation
- 1997-07-09 FI FI972922A patent/FI119354B/fi not_active IP Right Cessation
-
2005
- 2005-03-04 NL NL300180C patent/NL300180I2/nl unknown
- 2005-08-10 JP JP2005232408A patent/JP2005325139A/ja active Pending
-
2006
- 2006-05-03 LU LU91238C patent/LU91238I2/fr unknown
-
2010
- 2010-08-20 FR FR10C0041C patent/FR10C0041I2/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR10C0041I2 (fr) | ||
GB2291440B (en) | Fabric bleaching composition | |
HUT71634A (en) | Olefin production | |
NZ333588A (en) | Sulphamates as anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS) | |
MX9800589A (es) | Tratamiento de desorden de la falta de atencion/hiperactividad. | |
ES2145373T3 (es) | Procedimiento para el desdoblamiento de racemato de tramadol. | |
DE59600255D1 (de) | Werkzeug zum Spannen eines Bandes | |
AU128586S (en) | Lagging tread for a pulley | |
AU2904799A (en) | Therapeutic treatment for renal dysfunction | |
AU695058B2 (en) | Guide bar for a saw chain | |
FR2805755B1 (fr) | Machine de traitement de skis a entrainement lateral | |
ZA983298B (en) | Methods for reducing fibrinogen. | |
EP0859758A4 (fr) | ||
ES2141044B1 (es) | Terapia con oxibutinina. | |
FR2720249B1 (fr) | Procédé de manchage d'un ustensile de ménage, couvert notamment, et ustensile obtenu par un tel procédé. | |
IT230248Y1 (it) | Corpo per un tavolo, specialmente per una scrivania | |
ES1032198U (es) | Dispositivo soporte-envase para cepillos dentales. | |
ES1026343U (es) | Cabezal para escoba. |